Which Pharma Product Websites are Driving Consumers to the Doctor to Request Prescriptions?

Manhattan ResearchPharmaceutical and healthcare market research company Manhattan Research recently released the ePharma Consumer® v10.0 study, which explores the online behaviors of ePharma Consumers, or U.S. consumers using the Internet for prescription drug information. The study also provides in-depth metrics for hundreds of pharma product websites, including satisfaction, reasons for visiting, and post-visitation actions, as well as adoption and interest for various types of online resources and services from pharma.

The study found that pharma product websites are effective at driving post-visitation action. 74%* of ePharma Consumers visiting these websites take a product-related action afterward - either discussing product info with their doctor, family or friends; requesting or filling the prescription; or searching for more product info online.

Among the more than 320 pharma product websites tracked in the study, the brand website of erectile dysfunction treatment Levitra® was the most likely to drive visitors to request a prescription for the drug from their doctor. The brand websites for Chantix®, Cialis®, Nexium®, and Yaz® round out the top five most likely to drive visitors to request prescriptions.

A common theme among top websites is content and structure designed to lead consumers to talk to their doctor. Additionally, many of these products, such as the sleep aid Lunesta® and the acid reflux treatment Nexium®, feature doctor discussion guides or worksheets on their websites.

Top Pharma Product Websites Driving Visitors to Request that Prescription from the Doctor

1. Levitra®
2. Chantix®
3. Cialis®
4. Nexium®
5. Yaz®
6. Lyrica®
7. NuvaRing®
8. Symbicort®
9. Viagra®
10. Lunesta®

Websites with the highest percent of visitors responding that they "requested a prescription for this product from a doctor" after visiting website for themselves; Among U.S. adults ages 18+ online for pharma information and websites for which n>60

* Industry average of aided responses across more than 320 product websites visited

Complimentary ePharma Consumer® Data Snapshot
If you'd like to download a complimentary one-page snapshot of data and insights from the ePharma Consumer® v10.0 study, please visit http://www.manhattanresearch.com/research/data-snapshots/epharma-consumer-data-snapshot.aspx.

About ePharma Consumer® v10.0
ePharma Consumer® v10.0 was fielded online in Q4 2010 among 6,606 U.S. adults (ages 18+) who have gone online for pharma or prescription drug information in the past 12 months. This study also explores demand for adherence tools and services and the extent to which consumers leverage the Internet to lower drug spending. The study also provides key metrics for hundreds of pharma product websites.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a global pharmaceutical and healthcare market research and strategic advisory firm and conducts annual research studies covering eHealth trends among healthcare professionals and consumers.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions.

Most Popular Now

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Boehringer Ingelheim eExpands KRAS cancer program …

Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potent...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

Tagrisso approved in China as a 1st-line treatment…

AstraZeneca today announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-...